Medicament of dsRNA and saikosaponin

A technology of saikosaponin and bupleurum, which is applied in the drug field of dsRNA and saikosaponin, and can solve problems such as no compatibility of active substances, low fever, lack of suitable conditions for double-strand pairing, and systematic research on factors affecting stability.

Inactive Publication Date: 2014-04-30
胡鲸波
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, although there are domestic production of oligoinosinic acid and oligocytidylic acid raw materials, there is still a lack of systematic research on the suitable conditions for double-strand pairing and factors affecting stability, and there is no compatibility with other active substances. Aspects of reports
[0005] Pharmacological and toxicological studies at home and abroad have shown that after PIC is applied to animals, transient hypothermia side effects may occur, but how to prevent this side effect has not yet been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament of dsRNA and saikosaponin
  • Medicament of dsRNA and saikosaponin
  • Medicament of dsRNA and saikosaponin

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0016] Embodiment 1: This embodiment adopts the following technical scheme: its formula consists of: polykinocytes, saikosaponin and Bupleurum volatile oil; its preparation method is: adding appropriate pharmaceutical excipients to the above components by a certain amount The process is made into a compound preparation; these components have certain synergistic and synergistic effects, and can avoid the side effects of dsRNA.

specific Embodiment approach 2

[0017] Specific implementation mode two: refer to figure 1 , The specific embodiment adopts the following technical scheme: take two groups of test rabbits, inject the simple polyinocide injection and the combined medicine respectively to carry out the pyrogen test, and record the temperature changes of the test rabbits. The results showed that the combined drug could alleviate the pyrogen reaction of poly-inosin injection alone.

specific Embodiment approach 3

[0018] Specific implementation mode three: refer to figure 2 and image 3 , This specific embodiment adopts the following technical scheme: the medicine is diluted to 50 μg / ml with water for injection. 240 test chicks were randomly divided into 6 test groups, 40 in each group. Group I: blank control group; Group II: drug control group (astragalus polysaccharide injection, 20 mg per kilogram of body weight); Group III: vaccine control group (no drug); Group IV: high-dose drug test group (0.1 mg per kilogram of body weight). mg); V group: middle dose drug test group (0.05 mg per kg body weight); VI group: low dose drug test group (0.01 mg per kg body weight). The above chicks were reared in isolated cages, and the blank control group, the positive control group and the medication test group were raised in different chicken houses, and the feeding conditions were kept consistent. After feeding for 10 days, four groups III, IV, V and VI were immunized with Newcastle disease va...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicament of dsRNA and saikosaponin and application thereof, in particular to a medicament applied to prevention and treatment of viral infection of cultured animals, a preparation method and stability control method of the medicament. The medicament comprises the following ingredients: 20-50 mug / ml of saikosaponin, bupleurum oil with the content range of ultraviolet absorption value of above 0.45; and 1-3 mg / ml of polyinosinic polycytidylic acid with the molecular weight range of 200-500 bp (agarose gel electrophoresis method). The preparation method of the medicament comprises is in accordance with a water injection production technology: adding proper pharmaceutic adjuvant into the ingredients, preparing liquid, filtering, filling, encapsulating, sterilizing and examining for qualification. The medicament can induce generation of endogenous interferon in animal bodies, thus avoiding virus breeding in the animal bodies.

Description

Technical field: [0001] The invention relates to a medicine used in the prevention and treatment of viral infection of farmed animals and a preparation and stability control method of the combined medicine, in particular to a medicine of dsRNA and saikosaponin and its application. Background technique: [0002] Viral infection is an important factor that causes the death of farmed animals and affects the economic benefits of animal breeding. With the standardization of national veterinary drug quality standards, a large number of antiviral drugs with original local standards have been cancelled. Demand contradictions are becoming increasingly prominent. [0003] In 1967, Field et al. of Merck Pharmaceutical Company in the United States discovered that enzymatically synthesized double-stranded nucleic acid (doublestrained RNA, dsRNA) has the ability to induce interferon, and the ability to induce interferon of Polyinosinic-polycytidylic Acid (PIC) The strongest, it can stimu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/233A61P31/12A61K31/713A61K31/785
Inventor 胡鲸波
Owner 胡鲸波
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap